NextCure Director Gets 18,700 Stock Options at $0.47 Strike Price
NextCure director Stephen W. Webster received a stock option grant on June 20, 2025, representing a significant insider transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NextCure director Stephen W. Webster received a stock option grant on June 20, 2025, representing a significant insider transaction. Key details include:
- Granted 18,700 stock options to purchase common stock
- Exercise price set at $0.47 per share
- Options expire on June 19, 2035
- Full vesting occurs on the earlier of June 20, 2026 or the 2026 Annual Meeting
This director compensation grant suggests continued board engagement and alignment with shareholder interests through equity-based incentives. The relatively low exercise price compared to typical market prices for biotech stocks may indicate current market challenges or strategic considerations in retention of board talent.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 18,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did NXTC director Stephen Webster receive on June 20, 2025?
When do Stephen Webster's NXTC stock options vest?
What is the exercise price of NXTC's stock options granted to director Webster?
How long does Stephen Webster have to exercise his NXTC stock options?
What position does Stephen Webster hold at NextCure (NXTC)?
AI-generated analysis. How Rhea-AI works. Not financial advice.